

Registration for Webinar: December 9, 2019, until 12:30 p.m. EST January 21, 2020.

Registration to view the webinar is required.

ADDRESSES: Webinar web page <https://ntp.niehs.nih.gov/go/commprac-2020>.

FOR FURTHER INFORMATION CONTACT: Dr. Warren Casey, Director, NICEATM, Division of NTP, NIEHS, P.O. Box 12233, K2-17, Research Triangle Park, NC 27709. Phone: 984-287-3118, Email: warren.casey@nih.gov. Hand Deliver/Courier address: 530 Davis Drive, Room K2021, Morrisville, NC 27560.

SUPPLEMENTARY INFORMATION:

Background: ICCVAM promotes the development and validation of toxicity testing methods that protect human health and the environment while replacing, reducing, or refining animal use. ICCVAM also provides guidance to test method developers and facilitates collaborations that promote the development of new test methods. To address these goals, ICCVAM will hold a Communities of Practice webinar on "Use of Animal-free Affinity Reagents."

Affinity reagents such as antibodies are used in a range of research, diagnostic, and regulatory applications. However, traditional methods for producing such reagents require immunization of laboratory animals. Therefore, even when applied to nonanimal test methods, their use is inconsistent with the spirit of replacing, reducing, or refining animal use. Use of animal-based affinity reagents also introduces variability into the methods that use them.

This webinar will present a review of the usefulness and limitations of nonanimal-derived affinity reagents and their potential to replace animal-derived reagents. The preliminary agenda and additional information about presentations will be posted at <https://ntp.niehs.nih.gov/go/commprac-2020> as available.

Webinar and Registration: This webinar is open to the public with time scheduled for questions by participants following each presentation. Registration for the webinar is required and is open through 12:30 p.m. EST on January 21, 2020. Registration is available at <https://ntp.niehs.nih.gov/go/commprac-2020>. Interested individuals are encouraged to visit this web page to stay abreast of the most current webinar information. Registrants will receive instructions on how to access and participate in the webinar in the email confirming their registration.

Individuals with disabilities who need accommodation to participate in this event should contact Elizabeth

Mauill at phone: (984) 287-3157 or email: mauill@niehs.nih.gov. TTY users should contact the Federal TTY Relay Service at (800) 877-8339. Requests should be made at least five business days in advance of the event.

Background Information on ICCVAM and NICEATM: ICCVAM is an interagency committee composed of representatives from 16 federal regulatory and research agencies that require, use, generate, or disseminate toxicological and safety testing information. ICCVAM conducts technical evaluations of new, revised, and alternative safety testing methods and integrated testing strategies with regulatory applicability and promotes the scientific validation and regulatory acceptance of testing methods that more accurately assess the safety and hazards of chemicals and products and replace, reduce, or refine (enhance animal well-being and lessen or avoid pain and distress) animal use.

The ICCVAM Authorization Act of 2000 (42 U.S.C. 285I-3) establishes ICCVAM as a permanent interagency committee of NIEHS and provides the authority for ICCVAM involvement in activities relevant to the development of alternative test methods. Additional information about ICCVAM can be found at <https://ntp.niehs.nih.gov/go/iccvam>.

NICEATM administers ICCVAM, provides scientific and operational support for ICCVAM-related activities, and conducts and publishes analyses and evaluations of data from new, revised, and alternative testing approaches. NICEATM and ICCVAM work collaboratively to evaluate new and improved testing approaches applicable to the needs of U.S. federal agencies. NICEATM and ICCVAM welcome the public nomination of new, revised, and alternative test methods and strategies for validation studies and technical evaluations. Additional information about NICEATM can be found at <https://ntp.niehs.nih.gov/go/niceatm>.

Dated: November 18, 2019.

Brian R. Berridge,

Associate Director, National Toxicology Program.

[FR Doc. 2019-25667 Filed 11-25-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network Leadership and Operations Center (UM1—Clinical Trial Required).

Date: December 18, 2019.

Time: 10:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Roberta Binder, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3G21A, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, (240) 669-5050, rbinder@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: November 21, 2019.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-25684 Filed 11-25-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Topics in Gastroenterology.

Date: December 19, 2019.

Time: 10:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Rass M Shaiyq, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2182, MSC 7818, Bethesda, MD 20892, (301) 435-2359, shaiyqr@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine;

93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: November 20, 2019.

Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-25594 Filed 11-25-19; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Gene Therapy for Ocular Disease

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Eye Institute, the National Institute on Deafness and Other Communication Disorders, and the National Heart, Lung, and Blood Institute, institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an exclusive

patent license to OcQuila Therapeutics Ltd., a C corporation incorporated under the laws of the state of Delaware and a limited company incorporated under the laws of the United Kingdom, to practice the inventions covered by the patent estate listed in the **SUPPLEMENTARY INFORMATION** section of this notice.

DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center (representing the National Eye Institute and the National Heart, Lung, and Blood Institute (representing the National Institute on Deafness and Other Communication Disorders) on or before January 10, 2020 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an exclusive patent license should be directed to: Michael Shmilovich, Esq., Senior Licensing and Patent Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479, phone number 301-435-5019, or shmilovm@mail.nih.gov.

SUPPLEMENTARY INFORMATION:

INTELLECTUAL PROPERTY

NIH ref No.	Title	Patent application No.	Filing date	Issued patent No.	Issue date
E-284-2012-0-US-01	Methods And Compositions For Treating Genetically Linked Diseases Of The Eye.	61/765,654	February 15, 2013.		
E-284-2012-1-US-01	Methods And Compositions For Treating Genetically Linked Diseases Of The Eye.	61/815,636	April 24, 2013.		
E-284-2012-2-PCT-01	Methods And Compositions For Treating Genetically Linked Diseases Of The Eye.	PCT/US2014/16389	February 14, 2014.		
E-284-2012-2-AU-02	AAV8 retinoschisin expression vector for treating X-linked retinoschisis.	2014216160	February 14, 2014	2014216160	July 13, 2017.
E-284-2012-2-CA-03	AAV8 retinoschisin expression vector for treating X-linked retinoschisis.	2900231	February 14, 2014	2900231	July 30, 2019.
E-284-2012-2-JP-04	Methods And Compositions For Treating Genetically Linked Diseases Of The Eye.	2015-558144	February 14, 2014	6449175	December 14, 2018.
E-284-2012-2-US-05	Methods And Compositions For Treating Genetically Linked Diseases Of The Eye.	14/766,842	February 14, 2014	9,873,893	January 23, 2018.
E-284-2012-2-US-07	Methods And Compositions For Treating Genetically Linked Diseases Of The Eye.	15/876,821	February 14, 2014	10,350,306	July 16, 2019.
E-284-2012-2-EP-06	Methods And Compositions For Treating Genetically Linked Diseases Of The Eye.	14708176.4	February 14, 2014.		
E-284-2012-2-PCT-08	Methods And Compositions For Treating Genetically Linked Diseases Of The Eye.	PCT/US2019/14418	January 21, 2019.		
E-164-2018-0-US-01	Intraocular Delivery Of Gene Therapy Expression Vectors.	62/701,267	July 20, 2018.		
E-164-2018-1-US-01	Intraocular Delivery Of Gene Therapy Expression Vectors.	62/724,480	August 29, 2018.		
E-164-2018-2-US-01	Intraocular Delivery Of Gene Therapy Expression Vectors.	62/768,590	November 16, 2019.		
E-164-2018-3-PCT-01	Intraocular Delivery Of Gene Therapy Expression Vectors.	PCT/US2019/042365	July 18, 2019.		